GO:0032924 activin receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032924 (activin receptor signaling pathway) describes the biological process that begins when an extracellular activin ligand binds an activin receptor on the cell surface and ends with regulation of a downstream cellular process such as transcription.
• The pathway is initiated by activin A and related ligands engaging type II receptors (ACVR2A/ACVR2B), which recruit and phosphorylate type I receptors such as ALK4 and ALK2.
• Activated type I receptors phosphorylate SMAD2/3, which complex with SMAD4 and translocate to the nucleus to control target gene transcription.
• The pathway is a validated therapeutic axis: blocking activin type II receptors drives skeletal muscle hypertrophy and protects against atrophy, and the ligand trap dalantercept has been tested in oncology.
• Activin receptor signaling is implicated in cardiac aging and heart failure, pulmonary hypertension, and embryonic and skeletal muscle development.
• CRISPR knockout, point-mutation, knock-in and overexpression models are central tools for dissecting causal roles of activin receptor pathway genes.
Description
The activin receptor signaling pathway (GO:0032924) is a biological process defined as the series of molecular signals initiated by an extracellular ligand binding to an activin receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, for example transcription. Activin ligands belong to the transforming growth factor beta superfamily, and their receptors form a conserved serine/threonine kinase signaling system that converts an extracellular cue into changes in gene expression. Because the pathway controls cell growth, differentiation and tissue homeostasis, it is a recurring focus in developmental biology, oncology and muscle physiology. Mechanistically, activin signaling depends on two receptor classes: type II receptors that bind ligand and type I receptors that propagate the signal intracellularly. Ligand binding enables the type II receptor kinase to phosphorylate and activate the type I receptor, which in turn phosphorylates receptor-regulated SMAD proteins that carry the signal to the nucleus. This architecture makes the pathway highly tractable for genetic perturbation, and it explains why it has become a benchmark system for studying how extracellular signals are converted into transcriptional programs. For researchers, GO:0032924 matters because perturbations of this pathway produce measurable, often dramatic phenotypes. Antibody blockade of activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy, and dual anti-ActRIIA/IIB blockade is required to promote maximal hypertrophy. Activin type II receptor signaling also contributes to cardiac aging and heart failure, and ALK2 regulation in vascular smooth muscle cells has been linked to pulmonary hypertension. These findings position the pathway as both a mechanistic model and a therapeutic target.
activin receptor signaling pathway At A Glance
| GO ID | GO:0032924 |
|---|---|
| GO term | activin receptor signaling pathway |
| Ontology | biological_process |
| Synonym | activin receptor signalling pathway |
| Definition | The series of molecular signals initiated by an extracellular ligand binding to an activin receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. |
| Major function | Converts extracellular activin ligand binding into intracellular signals that regulate transcription and other downstream cellular processes. |
| Key receptors | Type II receptors (ACVR2A, ACVR2B) and type I receptors such as ALK4 and ALK2. |
| Key transducers | Receptor-regulated SMAD proteins, notably SMAD2 and SMAD3, acting with SMAD4. |
| Representative ligands | Activin A and related TGF-beta superfamily ligands. |
What Is GO:0032924?
In practical terms, GO:0032924 describes the complete signaling relay that starts at the cell surface when an activin ligand docks onto an activin receptor and finishes when that signal changes a downstream cellular process, most commonly transcription. The term therefore covers ligand recognition, receptor activation, intracellular signal transduction and the resulting regulation of gene expression, rather than any single molecule.
Why Is activin receptor signaling pathway Important in Cell Biology?
The activin receptor signaling pathway is important because it is a conserved mechanism by which extracellular cues control transcription, and because its pharmacological or genetic manipulation produces strong, quantifiable phenotypes in muscle, heart and vasculature. Blocking activin type II receptors induces skeletal muscle hypertrophy and protects from atrophy, and maximal hypertrophy requires dual blockade of ActRIIA and ActRIIB. The pathway is also being pursued therapeutically, with activin receptor inhibitors such as dalantercept evaluated in oncology. Together these features make GO:0032924 a high-value process for both basic discovery and translational research.
• Provides a defined mechanism linking extracellular activin ligands to transcriptional regulation.
• Controls skeletal muscle mass, with receptor blockade causing hypertrophy and protection from atrophy.
• Contributes to cardiac aging and heart failure through activin type II receptor signaling.
• Is implicated in pulmonary hypertension via ALK2 regulation in vascular smooth muscle cells.
• Plays roles in embryonic and skeletal muscle development.
• Is a druggable axis, exemplified by activin receptor inhibitors such as dalantercept.
• Offers clear, measurable phenotypes suitable for genetic perturbation studies.
• Serves as a model for understanding TGF-beta superfamily signal transduction.
What Happens During activin receptor signaling pathway?
Ligand binding to activin receptors
In simple terms: An activin signal molecule lands on a receptor on the cell surface, like a key fitting a lock.
The pathway begins when an extracellular activin ligand binds to an activin receptor on the surface of a target cell. This ligand-receptor interaction is the initiating event that defines the process, and it is the step that distinguishes activin receptor signaling from other TGF-beta superfamily pathways.
Type II receptor kinase activation
In simple terms: The receptor that grabbed the signal switches on and tags the next receptor in line.
Ligand binding enables the type II receptor, such as ACVR2A or ACVR2B, to act as an active kinase that phosphorylates and activates a type I receptor. This step converts ligand occupancy into enzymatic activity and is a central control point of the pathway.
Type I receptor activation and SMAD phosphorylation
In simple terms: The second receptor passes the message inward by tagging SMAD proteins.
The activated type I receptor, for example ALK4 or ALK2, phosphorylates receptor-regulated SMAD proteins, principally SMAD2 and SMAD3. This phosphorylation is the intracellular relay that carries the signal from the membrane toward the nucleus.
SMAD complex formation and nuclear transcription
In simple terms: The tagged SMAD proteins team up and travel to the nucleus to switch genes on or off.
Phosphorylated SMAD2/3 associate with SMAD4 and translocate to the nucleus, where the complex regulates transcription of target genes. This transcriptional output is the downstream cellular process that completes the definition of GO:0032924.
Pathway output and cellular consequences
In simple terms: The switched genes change how the cell behaves, such as growing or differentiating.
The transcriptional changes driven by activin receptor signaling produce cellular outcomes that include effects on muscle mass and cardiac and vascular biology. Blocking the pathway at the receptor level alters these outputs, demonstrating that the signaling relay is causally linked to the phenotype.
Key Genes Involved in GO:0032924 activin receptor signaling pathway
The following genes and proteins are core components or well-documented modulators of the activin receptor signaling pathway (GO:0032924).
| Gene | Major Role | Research Relevance |
|---|---|---|
| ACVR2A | Type II activin receptor that binds ligand and activates type I receptors | Target of blocking antibodies that induce muscle hypertrophy |
| ACVR2B | Type II activin receptor mediating activin signal initiation | Dual blockade with ACVR2A is required for maximal hypertrophy |
| ACVR1 | Type I receptor (ALK2) that propagates activin receptor signals | Regulation in vascular smooth muscle cells is implicated in pulmonary hypertension |
| ACVR1B | Type I receptor (ALK4) that phosphorylates SMAD2/3 | Central node for intracellular signal propagation |
| SMAD2 | Receptor-regulated SMAD phosphorylated by type I receptors | Readout of pathway activation and transcriptional output |
| SMAD3 | Receptor-regulated SMAD partnering with SMAD2 | Key transducer linking receptor activation to transcription |
| SMAD4 | Common SMAD forming complexes with SMAD2/3 | Required for nuclear transcriptional regulation |
| INHBA | Encodes activin A, a principal pathway ligand | Ligand-side control of pathway initiation |
| INHBB | Encodes activin B, an activin ligand | Contributes to ligand diversity in activin signaling |
| BRCC3 | Regulates ALK2 in vascular smooth muscle cells | Mechanistic link to pulmonary hypertension |
| FKBP12 | Modulates type I receptor activity in TGF-beta superfamily signaling | Potential tuning node for receptor output |
| SMAD7 | Inhibitory SMAD that restrains pathway signaling | Negative feedback control of activin signaling |
| SMURF1 | E3 ubiquitin ligase regulating SMAD and receptor turnover | Post-translational control of pathway components |
| SMURF2 | E3 ubiquitin ligase regulating receptor and SMAD stability | Regulatory layer affecting signal duration |
| ACVR2A/ACVR2B complex | Receptor pair targeted by blocking antibodies | Therapeutic and experimental intervention point |
| Dalantercept target (ACVR1B/ACVR2A axis) | Ligand trap inhibiting activin receptor signaling | Clinical-stage inhibition of the pathway |
How Is activin receptor signaling pathway Regulated?
Activin receptor signaling is regulated at multiple levels. Inhibitory SMAD7 and E3 ubiquitin ligases such as SMURF1 and SMURF2 restrain receptor and SMAD activity, providing negative feedback that limits signal duration. Receptor availability and activity are also modulated by accessory proteins, and the pathway can be blocked pharmacologically at the receptor level by antibodies directed against activin type II receptors. In disease contexts, regulation of type I receptor components such as ALK2 by proteins like BRCC3 influences pathway output in vascular smooth muscle cells. These layers of control allow the pathway to be tuned rather than simply switched on or off.
activin receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ACVR2A | Muscle atrophy and hypertrophy | Knockout or antibody-blockade models in muscle cells |
| ACVR2B | Muscle hypertrophy requiring dual receptor blockade | Dual knockout or dual-blocking antibody studies |
| ACVR1 | Pulmonary hypertension via vascular smooth muscle ALK2 | Vascular smooth muscle cell knockout of ALK2 |
| SMAD2/SMAD3 | Transcriptional output relevant to cardiac and muscle biology | Point-mutation or knockout of SMAD phosphorylation sites |
| INHBA | Ligand-driven pathway activation in development and disease | Overexpression or knockout of activin A |
Cardiac aging and heart failure
Activin type II receptor signaling has been implicated in cardiac aging and heart failure, linking the pathway to age-related decline in cardiac function. This makes the pathway a candidate axis for understanding and potentially intervening in heart failure biology.
Pulmonary hypertension
Regulation of ALK2 by BRCC3 in vascular smooth muscle cells has been connected to pulmonary hypertension, indicating that activin receptor signaling components contribute to vascular remodeling in this disease.
Muscle wasting and atrophy
Blockade of activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy, and dual anti-ActRIIA/IIB blockade is critical for maximal hypertrophy. This establishes the pathway as a therapeutic target for muscle-wasting conditions.
Cancer and therapeutic inhibition
Activin receptor inhibitors such as dalantercept have been developed and evaluated as anticancer agents, reflecting interest in the pathway as a druggable target in oncology. This work illustrates how blocking activin receptor signaling can be translated into clinical strategies.
From activin receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a receptor required for pathway activation? | CRISPR knockout of ACVR2A or ACVR2B |
| Does a specific phosphorylation site control signaling? | Point mutation of SMAD2/3 phosphorylation sites |
| Can a tagged receptor be tracked in cells? | Knock-in of an epitope-tagged type I or type II receptor |
| Does increased ligand drive pathway output? | Overexpression of INHBA or related activin ligands |
| Does dual receptor blockade enhance phenotype? | Combined knockout or dual-blocking antibody models |
| Does ALK2 regulation affect vascular cells? | Knockout or knockdown of ALK2 in vascular smooth muscle cells |
How to Study the activin receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptional changes downstream of pathway activation | Identifying target genes regulated by activin signaling |
| Phospho-SMAD immunoblotting | SMAD2/3 phosphorylation status | Confirming receptor-proximal pathway activation |
| CRISPR knockout | Requirement of a gene for pathway function | Testing receptor or transducer necessity |
| CRISPR point mutation | Effect of specific residues on signaling | Mapping phosphorylation-dependent regulation |
| CRISPR knock-in tagging | Localization and interactions of pathway proteins | Tracking receptor or SMAD dynamics |
| Overexpression | Consequences of increased ligand or receptor levels | Modeling ligand-driven activation |
| Antibody blockade assays | Functional impact of receptor inhibition | Evaluating therapeutic blockade of the pathway |
| Ligand trap assays | Sequestration of activin ligands | Testing pharmacological pathway inhibition |
Transcriptional readouts of pathway activity
Because the pathway ends with regulation of transcription, RNA-based readouts are a natural way to measure its output. Comparing transcriptional profiles after ligand stimulation or receptor perturbation reveals which genes are controlled by activin receptor signaling.
Protein-level analysis of SMAD phosphorylation
Phosphorylation of SMAD2 and SMAD3 is a direct biochemical consequence of type I receptor activity, so phospho-specific detection provides a proximal measure of pathway activation. This approach is widely used to confirm that a perturbation acts on the pathway itself rather than downstream.
Genetic perturbation with CRISPR
CRISPR knockout, point mutation, knock-in and overexpression allow causal testing of individual pathway components. Such models have been used to show that blocking activin type II receptors produces muscle hypertrophy and protects from atrophy.
Pharmacological and antibody-based inhibition
Antibodies blocking activin type II receptors and ligand traps such as dalantercept provide complementary tools to genetic perturbation for interrogating pathway function. These reagents are especially useful when receptor redundancy requires simultaneous inhibition of multiple components.
How CRISPR Can Be Used to Study GO:0032924 activin receptor signaling pathway
Knockout
CRISPR knockout of activin receptor pathway genes such as ACVR2A, ACVR2B or SMAD transducers removes the component and tests whether it is required for signaling. Knockout approaches have been used to demonstrate that blocking activin type II receptors produces muscle hypertrophy and protects from atrophy.
Point Mutation
Point mutation can be used to alter specific residues, such as SMAD phosphorylation sites, to determine how individual molecular features contribute to pathway output. This provides a finer resolution than complete gene deletion and helps separate distinct signaling functions.
Knock-in
Knock-in of tags or reporters into pathway genes allows the localization, abundance and interactions of receptors and SMAD proteins to be monitored in a physiological context. Such models support mechanistic studies of how the pathway relays signals from the membrane to the nucleus.
Overexpression
Overexpression of activin ligands such as INHBA or of pathway receptors can drive pathway activation and reveal downstream consequences. This approach is useful for modeling states of ligand excess and for testing whether increased signaling is sufficient to produce a phenotype.
How EDITGENE Supports activin receptor signaling pathway Research
Researchers studying activin receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in signal initiation, transduction or transcriptional output, and this requires precise, reproducible genetic models. EDITGENE provides the full range of CRISPR-based cell model services needed to move from correlation to causation in GO:0032924 research.
Contact EDITGENE today to design your custom CRISPR model for activin receptor signaling pathway research.
Frequently Asked Questions About activin receptor signaling pathway
What is the activin receptor signaling pathway (GO:0032924)?
It is the biological process that starts when an extracellular activin ligand binds an activin receptor on the cell surface and ends with regulation of a downstream cellular process such as transcription.
What genes are involved in activin receptor signaling pathway?
Core genes include the type II receptors ACVR2A and ACVR2B, type I receptors such as ACVR1 (ALK2) and ACVR1B (ALK4), the SMAD transducers SMAD2, SMAD3 and SMAD4, and ligands such as INHBA.
How does activin receptor signaling work?
Ligand binding activates type II receptor kinases, which phosphorylate type I receptors; the type I receptors then phosphorylate SMAD2/3, which complex with SMAD4 and regulate transcription in the nucleus.
Why is activin receptor signaling important for muscle?
Blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy, and dual anti-ActRIIA/IIB blockade is critical for maximal hypertrophy.
Is activin receptor signaling involved in heart disease?
Yes, activin type II receptor signaling has been implicated in cardiac aging and heart failure.
What diseases are linked to activin receptor signaling?
The pathway has been linked to muscle atrophy, cardiac aging and heart failure, pulmonary hypertension, and cancer, where inhibitors such as dalantercept have been studied.
How can I study activin receptor signaling with CRISPR?
CRISPR knockout, point mutation, knock-in and overexpression can be used to test the requirement and function of receptors, ligands and SMAD transducers in the pathway.
What is the role of SMAD2 and SMAD3 in this pathway?
SMAD2 and SMAD3 are receptor-regulated SMAD proteins phosphorylated by type I receptors; they partner with SMAD4 to regulate transcription.
Can activin receptor signaling be inhibited therapeutically?
Yes, antibodies blocking activin type II receptors and ligand traps such as dalantercept have been developed to inhibit the pathway.
What is the difference between activin type I and type II receptors?
Type II receptors bind ligand and phosphorylate type I receptors, while type I receptors propagate the signal by phosphorylating SMAD proteins.
Conclusion
GO:0032924, the activin receptor signaling pathway, is a well-defined biological process that converts extracellular activin ligand binding into transcriptional regulation through type II receptors, type I receptors and SMAD transducers. Its importance spans muscle biology, cardiac and vascular disease, and cancer, with strong evidence that receptor blockade produces measurable phenotypes such as skeletal muscle hypertrophy. Because the pathway is genetically tractable, CRISPR-based knockout, point-mutation, knock-in and overexpression models are powerful tools for establishing causality among its components. For researchers, the combination of a precise ontology definition, a clear molecular mechanism and validated disease links makes activin receptor signaling an attractive system for both mechanistic discovery and therapeutic development. EDITGENE supports this work with end-to-end cell model and screening services tailored to activin receptor pathway genes.
References
- 1. Lodberg A. 2021. Principles of the activin receptor signaling pathway and its inhibition.. Cytokine Growth Factor Rev 60:1-17 PMID: 33933900
- 2. Roh JD et al.. 2019. Activin type II receptor signaling in cardiac aging and heart failure.. Sci Transl Med 11(482) PMID: 30842316
- 3. Abe Y et al.. 2004. Activin receptor signaling.. Growth Factors 22(2):105-10 PMID: 15253386
- 4. Shen H et al.. 2024. BRCC3 Regulation of ALK2 in Vascular Smooth Muscle Cells: Implication in Pulmonary Hypertension.. Circulation 150(2):132-150 PMID: 38557054
- 5. Richman J et al.. 2024. Activin Signaling Pathway Specialization During Embryonic and Skeletal Muscle Development in Rainbow Trout (Oncorhynchus mykiss).. Mar Biotechnol (NY) 26(4):766-775 PMID: 39052141
- 6. Lach-Trifilieff E et al.. 2014. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy.. Mol Cell Biol 34(4):606-18 PMID: 24298022
- 7. Gupta S et al.. 2015. Activin receptor inhibitors--dalantercept.. Curr Oncol Rep 17(4):14 PMID: 25708802
- 8. Morvan F et al.. 2017. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.. Proc Natl Acad Sci U S A 114(47):12448-12453 PMID: 29109273
